Atezolizumab in non-squamous non-small cell lung cancer

Immune therapy opened a new era in treatment of advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) targeting the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) pathway have achieved great success over conventional cytotoxic chemotherapy.